World Orphan Drug Congress agenda

In Advocacy, Clinical Development, Regulation & Government by Freya Smale


Here it is!

The brochure for the World Orphan Drug Congress is ready and we are releasing it to Total Orphan first. 

Highlights from the agenda include:

Ultra-orphan therapies – broad skills for small populations
Martin Mackay, EVP & Global Head of R&D, Alexion Pharmaceuticals

How to optimise clinical development and demonstrate value for an orphan drug
Rogerio Vivaldi, SVP and Head of Rare Diseases, Genzyme

Understanding the complexity of rare disease research
Arthur Tzianabos, SVP, Head of Research, Shire HGT

Discover new policy principles scenarios on rare disease patient registries
Yann Le Cam, Chief Executive Officer, Eurordis

Confirmed speakers from payers and HTA bodies:


· HAS – France

· CVZ – Netherlands

· RIZIV-INAMI – Belgium

· HVB – Austria

· Ministry of Health – Spain

· EUnetHTA

Click here to see the full agenda by downloading your copy of the brochure >

Book now to join them and join the discussion >